Skip to main navigation
AASLD Family of Websites: The Liver Meeting
AASLD.org AASLD Foundation LiverLearning Careers Journals Liver Fellow Network HCV Guidelines
Home

TLM Main Navigation

  • Claim CE Credits
  • For Industry
    Why Exhibit Reserve a Booth Exhibitor Resources
  • Attend
    Housing Venue Visa Letter
  • Program
    Call for Abstracts Open On-Site Guides
  • Submit an Abstract

Genetic and Metabolic Disease: Diagnosis, Outcomes, and Treatment

Nov 12 2023
Room 302 - Hynes Convention Center
4:30 - 6:00 PM EST

Speakers

Valentina Medici

University of California, Davis

Arvind R. Murali

University of Iowa Hospitals and Clinics

Anandini Suri

Saint Louis University

Peter Ott

Aarhus University

Clavia R. Wooton-Kee

Baylor College of Medicine

Description

Abstracts

  • ARBM-101 AS A SAFE AND POTENT THERAPEUTIC OPTION FOR WILSON DISEASE
  • DECREASED PREGNANE X RECEPTOR (PXR) EXPRESSION PROMOTES LIVER NODULE DEVELOPMENT IN Atp7b-/- MICE
  • METABOLIC SYNDROME ASSOCIATED FATTY LIVER DISEASE IS A SIGNIFICANT RISK FACTOR FOR THE DEVELOPMENT OF HEPATIC EVENTS IN ALPHA-1-ANTITRYPSIN PI*ZZ INDIVIDUALS.
  • EVALUATION OF NON-CERULOPLASMIN COPPER BY PROTEIN SPECIATION (NCC-SP) AND 24-HOUR URINARY COPPER EXCRETION (UCE) FOR MONITORING CHELATOR TREATMENT IN PATIENTS WITH WILSON DISEASE.
  • SERUM Z POLYMER LEVELS AND FACTORS AFFECTING INCREASED LIVER FIBROSIS ARE ASSOCIATED WITH FUTURE SEVERE LIVER DISEASE OUTCOMES IN A PROSPECTIVE COHORT OF ADULTS WITH ALPHA-1-ANTITRYPSIN DEFICIENCY .
About Us
  • AASLD Foundation
  • About AASLD
Legal
  • Abstract Policies
  • Accreditation and Designation Statements
  • Disclosure Policy
  • Embargo Policy
  • Ethics Policy
  • Event Registration Policies
  • Limited License for Use
Get In Touch
  • Contact
Follow Us
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Copyright © 2025 American Association for the Study of Liver Diseases
AASLD: The Liver Meetings - Nov. 15-19, 2024